Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials

OBJECTIVES: Dolutegravir (DTG) has been studied in three trials in HIV treatment-naive participants, showing noninferiority compared with raltegravir (RAL), and superiority compared with efavirenz and ritonavir-boosted darunavir. We explored factors that predicted treatment success, the consistency...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:AIDS
Main Authors: Raffi, François, Rachlis, Anita, Brinson, Cynthia, Arasteh, Keikawus, Górgolas, Miguel, Brennan, Clare, Pappa, Keith, Almond, Steve, Granier, Catherine, Nichols, W. Garrett, Cuffe, Robert Liam, Jr, Joseph Eron, Walmsley, Sharon
Formato: Artigo
Idioma:Inglês
Publicado em: Lippincott Williams & Wilkins 2015
Assuntos:
Clinical Science
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4284010/
https://ncbi.nlm.nih.gov/pubmed/25387312
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/QAD.0000000000000519
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados